Where is Turbine headquartered?

Turbine is headquartered in Budapest, Hungary (HQ); London, UK; Cambridge, UK. The company has a team of 101-500 people.

When was Turbine founded?

Turbine was founded in 2016. It is based in Budapest, Hungary (HQ); London, UK; Cambridge, UK.

Who is the CEO of Turbine?

Szabolcs Nagy is the CEO of Turbine. The company was founded in 2016.

Where is Turbine located?

Turbine is headquartered in Budapest, Hungary (HQ); London, UK; Cambridge, UK.

What funding stage is Turbine at?

Turbine is currently at the Growth Stage stage.

How many employees does Turbine have?

Turbine has approximately 101-500 employees.

Turbine

Category: AI in Healthcare

Turbine virtualizes biological experiments with AI to accelerate drug discovery and improve clinical translatability through its Simulated Cell platform. Turbine was founded in 2016. The company is led by Szabolcs Nagy. Based in Budapest, Hungary (HQ); London, UK; Cambridge, UK. Team size: 101-500. Total funding raised: $62M. Latest round: Series B. Key investors include Accel, MSD Global Health Innovation Fund (Merck & Co.), Mercia, Interactive Venture Partners, Beiersdorf Venture Capital, MassMutual Ventures, Delin Ventures, XTX Ventures, Day One Capital, Accenture Ventures, Atlantic Labs, o2h Ventures.

Founded: 2016
Headquarters: Budapest, Hungary (HQ); London, UK; Cambridge, UK
Team size: 101-500
Total funding: $62M

Value proposition

Turbine's Simulated Cell platform uses AI to create virtual copies of biological experiments, enabling researchers to run millions of in silico experiments in hours instead of weeks, improving clinical translatability and reducing drug development failure rates.

Products and solutions

Simulated Cell platform (foundational virtual cell model), Virtual Lab (no-code simulation platform), ADC Intelligence, Target Discovery & De-risking, Virtual Cells, Lab-in-the-loop validation

Unique value

World's leading predictive simulation of patient biology — models the fundamental protein signaling logic that decides cell fate, enabling mechanistic understanding rather than correlative predictions, with a lab-in-the-loop that continuously improves model accuracy.

Target customer

Global biopharmaceutical companies (R&D teams in oncology, immunology, and drug discovery); CROs; academic research institutions

Industries served

Oncology drug discovery, Immunology, Antibody-drug conjugate (ADC) development, Translational medicine, Dermatology/cosmetics (via Beiersdorf partnership)

Technology advantage

Proprietary Simulated Cell platform that models protein signaling logic (not just correlative ML); ability to simulate 50M experiments/day; mechanistic (causal) predictions vs. black-box AI; lab-in-the-loop active learning; validated across 30+ discovery programs with top pharma partners

How they differentiate

Unlike most AI drug discovery companies that use correlative ML or generative models, Turbine builds mechanistic, causal models of cell signaling that explain why a drug works, not just that it might work. Its lab-in-the-loop creates a continuous feedback cycle where in silico predictions are validated in wet lab and data flows back to improve the model.

Main competitors

Insilico Medicine, Recursion Pharmaceuticals, BenevolentAI, Isomorphic Labs, Valo Health

Key partnerships

AstraZeneca, Bayer, Ono Pharmaceutical, MSD (Merck & Co.) via MSD Global Health Innovation Fund, Cancer Research Horizons, Crown Bioscience (strategic partnership, April 2026), Beiersdorf (investor + potential dermatology collaboration), Champions Oncology (strategic collaboration, April 2025)

Notable customers

AstraZeneca, Bayer, Ono Pharmaceutical, MSD (Merck & Co.), Top 10 pharma company (immunology partnership, announced Feb 2026, name undisclosed)

Major milestones

2016: Company founded, 2019: €3M Seed round led by Delin Ventures, 2021: $6.85M Pre-Series A led by Accel, 2022: €20M Series A co-led by Mercia and MSD GHI Fund, 2023: Series A upsized to €25.5M with MassMutual Ventures, 2024: Strategic investment from Accenture Ventures, 2024: Key milestone achieved with Ono Pharmaceutical collaboration, 2025: Strategic collaboration with Champions Oncology, 2026: $25M Series B led by Interactive Venture Partners, 2026: First immunology partnership with top 10 pharma company, 2026: Strategic partnership with Crown Bioscience

Growth metrics

~106-115 employees (2026); 30+ discovery programs with pharma partners; 1,400+ oncology cell lines in platform; 1,200+ drugs/drug-like molecules; 8,500+ genes with KO alterations

Market positioning

Leading AI-powered virtual biology platform in Europe, competing with global AI drug discovery players. Positioned as a platform provider to pharma (not a drug developer itself), with expansion from oncology into immunology and dermatology.

Geographic focus

Global (HQ in UK, operations in Hungary, partnerships with pharma across US, Europe, and Japan)

About Szabolcs Nagy

Co-founded a cybersecurity startup (acquired); Chief Strategy Officer at The Medical Futurist; studied International Business at Corvinus University of Budapest

Latest news about Turbine

Turbine raised $25M Series B led by Interactive Venture Partners with participation from Beiersdorf Venture Capital, marking their expansion into immunology through a new partnership with a top 10 pha

More AI in Healthcare companies

Official website: https://turbine.ai